Eli Lilly & Co. (LLY)

116.59
NYSE : Health Technology
Prev Close 119.16
Day Low/High 115.02 / 116.90
52 Wk Low/High 73.69 / 119.84
Avg Volume 4.50M
Exchange NYSE
Shares Outstanding 1.06B
Market Cap 126.23B
EPS -0.20
P/E Ratio 253.53
Div & Yield 2.58 (1.93%)

Latest News

Notable Friday Option Activity: LLY, ATEN, FRO

Notable Friday Option Activity: LLY, ATEN, FRO

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Lilly (Eli) & Co , where a total volume of 44,518 contracts has been traded thus far today, a contract volume which is representative of approximately 4.5 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 86.7% of LLY's average daily trading volume over the past month, of 5.1 million shares.

Lilly Reports Results Of Phase 3 Soft Tissue Sarcoma Study Of LARTRUVO®

Lilly Reports Results Of Phase 3 Soft Tissue Sarcoma Study Of LARTRUVO®

- Study did not meet the primary endpoints of overall survival (OS) in the full study population or in the leiomyosarcoma (LMS) sub-population; there was no difference in survival between the study arms for either population.

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative

So far 2019 is proving to be a year where things have a habit of working out right.

Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

Banks Are Leading: Cramer's 'Mad Money' Recap (Wednesday 1/16/19)

Jim Cramer looks at the run in the financial stocks and says banks are leading this market back.

Ligand Pharmaceuticals Tumbles After Short-Seller Andrew Left Slams the Stock

Ligand Pharmaceuticals Tumbles After Short-Seller Andrew Left Slams the Stock

Left's firm Citron Research gives the $100+ stock a $35 price target.

Jim Cramer: There's a Ton More Deals in the Pipe

Jim Cramer: There's a Ton More Deals in the Pipe

Deals that simply were unworkable four months ago because of price are now being done with alacrity.

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman's Gold Standard in M&A Bolsters Outlook for 2019

Goldman is top of the heap for takeovers.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Big pharma is shaping up to be a consolidating category in 2019.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

The Gold Rush of 2019

The Gold Rush of 2019

Newmont Mining will acquire Goldcorp in a $10 billion deal, and here's how I'd trade Newmont.

Pfizer and the Urge to Merge

Pfizer and the Urge to Merge

My stated reason for being in Pfizer all along has been price stability and income.

This Market May Just Be in an Uptrend: Market Recon

This Market May Just Be in an Uptrend: Market Recon

This is the kind of reversal that happens in a bull market.

WEISSLAW LLP: Loxo Oncology, Inc. Acquisition May Not Be In The Best Interests Of LOXO Shareholders

WEISSLAW LLP: Loxo Oncology, Inc. Acquisition May Not Be In The Best Interests Of LOXO Shareholders

NEW YORK, Jan. 8, 2019 /PRNewswire/ --  WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Loxo Oncology, Inc.

In Case You Missed it: M&A Is Hot to Start January, GE Could Fetch $40 Billion

In Case You Missed it: M&A Is Hot to Start January, GE Could Fetch $40 Billion

Could there be more M&A this year than Wall Street had thought? Also, GE's quest for more liquidity took another baby step Monday.

Hunt for Winning Stocks: Cramer's 'Mad Money' Recap (Monday 1/7/19)

Hunt for Winning Stocks: Cramer's 'Mad Money' Recap (Monday 1/7/19)

Jim Cramer says companies that innovate become market-leading stocks, and can create tremendous wealth.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Loxo Oncology, Inc.

ALERT: Rowley Law PLLC Is Investigating Proposed Acquisition Of Loxo Oncology, Inc.

NEW YORK, Jan. 7, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Loxo Oncology, Inc.

3 Things to Know at Market Close: Tesla Grows In China, Pharma Binds, GE Unwinds

3 Things to Know at Market Close: Tesla Grows In China, Pharma Binds, GE Unwinds

Tesla, the big pharma mergers and General Electric are some of the top stories on TheStreet.

Luxoft Soars After Announcing $2 Billion Deal to Be Bought by DXC Technology

Luxoft Soars After Announcing $2 Billion Deal to Be Bought by DXC Technology

Luxoft is to be bought for about $2 billion by DXC Technology.

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

The Dow Jones Industrial Average is higher Monday amid improved prospects for a trade deal between the U.S. and China.

Celgene Expects to Generate Up to $17.2 Billion in Revenue in 2019

Celgene Expects to Generate Up to $17.2 Billion in Revenue in 2019

The company expects revenue to jump 12% year over year.

Eli Lilly to Buy Loxo Oncology for $8 Billion in Second Major 2019 Drug Takeover

Eli Lilly to Buy Loxo Oncology for $8 Billion in Second Major 2019 Drug Takeover

Eli Lilly & Co. says Monday it will pay $8 billion in cash for cancer drug specialists Loxo Oncology in the second major pharmaceutical sector deal of the year.

Bigfoot Biomedical Announces Next Step For Connected Insulin Injection System

Bigfoot Biomedical Announces Next Step For Connected Insulin Injection System

Bigfoot Biomedical, Inc., a diabetes company using artificial intelligence to develop solutions for optimizing the dosing and delivery of insulin, today announced a non-exclusive cooperation agreement with Eli Lilly and Company (NYSE: LLY) to support...

US Futures Flat, Europe Slides, as Fed Rally Fades Despite Trade Talk Progress

US Futures Flat, Europe Slides, as Fed Rally Fades Despite Trade Talk Progress

Global stocks traded higher Monday, following on from Friday's spectacular rally on Wall Street, as investors cheered much stronger-than-expected U.S. jobs data paired with twin dovish messages from the Federal Reserve and the People's Bank of China that look to support beaten-down asset prices heading into the fourth quarter earnings season.

Jim Cramer: These Pharma Deals Are Game Changers

Jim Cramer: These Pharma Deals Are Game Changers

Pharma companies that have cash are looking at what has happened to this stock market and buying.

Lilly Announces Agreement To Acquire Loxo Oncology

Lilly Announces Agreement To Acquire Loxo Oncology

INDIANAPOLIS and STAMFORD, Conn., Jan.

Lilly To Participate In J.P. Morgan Healthcare Conference

Lilly To Participate In J.P. Morgan Healthcare Conference

INDIANAPOLIS, Jan. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the 37 th Annual J.

TheStreet Quant Rating: B+ (Buy)